MYEOV (myeloma overexpressed (in a subset of t (11;14) positive multiple myelomas))

2011-10-01   Jérôme Moreaux  

Identity

HGNC
MYEOV
LOCATION
11q13.3
LOCUSID
26579
ALIAS
OCIM
FUSION GENES
Show Gene Fusions

DNA/RNA

Note

The MYEOV gene was originally isolated by the application of the NIH/3T3 tumorigenicity assay with DNA from a gastric carcinoma. The chromosomal region 11q13 is frequently associated with genetic rearrangements in a large number of human malignancies, including B-cell malignancies and overexpression of MYEOV is frequently observed in breast tumors and oral, esophageal squamous cell carcinomas and multiple myeloma. The presence of functional domains such as RNP-1 (motif typical of RNA binding protein) and the studies of the short hydrophobic regions and of the C-terminal leucine/isoleucine tail showed that MYEOV might be directed to the membrane. MYEOV small interfering RNA (siRNA) decreased proliferation of gastric cancer cells, colon cancer cell lines and multiple myeloma cells in vitro.
Atlas Image

Description

2 exons; 3,5 kb transcript represents unspliced mRNA.

Transcription

Main transcript 2,8 kb (broad band because of alternative splice products); minor transcript 3,5 kb; coding sequence 313 or 255 amino acids. In normal tissues hardly any expression detectable. High expression in a subset of multiple myeloma cell lines with a t(11;14)(q13;q32) and in breast tumors and esophageal squamous cell carcinomas with or without 11q13 amplification.

Pseudogene

No pseudogenes have been reported for MYEOV.

Proteins

Description

313 or 255 amino acids; contains one RNP-1 motif and 6 regions that might function as a transmembrane domain. Leucine-rich stretch at C-terminal.

Expression

5 UTR inhibits efficient translation of the protein.

Localisation

In endoplasmic reticulum and mitochondria.

Homology

No known homology.

Implicated in

Entity name
t(11;14)(q13;q32)
Disease
Subset of multiple myeloma cell lines with t(11;14)(q13;q32).
Cytogenetics
MYEOV overexpression due to juxtaposition to the 5 enhancer or the most telomeric 3 enhancer of the immunoglobulin heavy chain (IgH).
Entity name
11q13 amplification and/or overexpression
Disease
Breast cancer; esophageal squamous cell carcinomas.
Prognosis
MYEOV DNA amplification correlated with estrogen and progesterone receptor-positive cancer, invasive lobular carcinoma type and axillary nodal involvement. In contrast to Cyclin D1 amplification, no association with disease outcome could be found.
Entity name
Multiple myeloma
Prognosis
In a cohort of 171 myeloma patients, patients with MYEOVabsent MMC have an increased event-free survival compared to patients with MYEOVpresent MMC, after high-dose therapy and stem cell transplantation and a trend for increased overall survival. In a Cox proportional hazard model, MYEOV expression in MMC is predictive for event-free survival for patients independently of International Staging System stage, t(4;14) translocation, albumin, or B2M serum levels. In a second independent cohort of 208 patients (LR-TT3, from the University of Arkansas for Medical Sciences (Little Rock, AR, USA)), MYEOV had a "present" call in MMCs of 73% of patients. Patients with MYEOVabsent MMCs had a significant better overall survival in the LR-TT3 cohort.
Oncogenesis
In a cohort of 171 patients, MMC of 79% of the patients with newly diagnosed MM express MYEOV gene. A treatment with 5-aza-2-deoxycytidine of 2 MYEOVabsent myeloma cell lines induced MYEOV expression without affecting that in the MYEOVpresent myeloma cells. MYEOV siRNA did not significantly induce apoptosis in myeloma cell lines, but it blocked the cell cycle entry into the S-phase.
Entity name
Colon cancer
Oncogenesis
Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation of colon cancer cell lines in vitro. Furthermore, in colon cancer, MYEOV stimulates colorectal cancer cell migration in vitro. MYEOV expression is enhanced by PGE2 treatment in colorectal cancer cells.
Entity name
Gastric cancer
Oncogenesis
Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation and invasion of gastric cancer cells in vitro.
Entity name
Neuroblastoma
Oncogenesis
MYEOV is a candidate gene target in neuroblastoma that was identified by chromosomal gain 11q13 through SNP analysis. MYEOV expression was analyzed in 55 neuroblastoma samples including 25 cell lines. MYEOV was shown to be upregulated in 11 out of 25 neuroblastoma cell lines and 7 out of 20 fresh tumors. Knockout of MYEOV RNA (siRNA) has been shown to decrease proliferation of neuroblastoma cell line in vitro.
Entity name
Oral squamous cell carcinoma
Oncogenesis
Gain of 11q13 was significantly associated with cervical lymph node metastasis in oral squamous cell carcinoma (54 patients included in the study). Copy number amplification of MYEOV is associated with cervical lymph node metastasis in oral squamous cell carcinoma. Lymph node metastasis is associated with a significant decrease of 5-years survival in oral squamous cell carcinoma.

Article Bibliography

Pubmed IDLast YearTitleAuthors
122029832002MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas.Janssen JW et al
205694982010MYEOV (myeloma overexpressed gene) drives colon cancer cell migration and is regulated by PGE2.Lawlor G et al
165524342006Net1 and Myeov: computationally identified mediators of gastric cancer.Leyden J et al
208548742010MYEOV is a prognostic factor in multiple myeloma.Moreaux J et al
166781232006ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion.Moss AC et al
217017732011Combination effects of distinct cores in 11q13 amplification region on cervical lymph node metastasis of oral squamous cell carcinoma.Sugahara K et al
216240082011Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma.Takita J et al

Other Information

Locus ID:

NCBI: 26579
MIM: 605625
HGNC: 7563
Ensembl: ENSG00000172927

Variants:

dbSNP: 26579
ClinVar: 26579
TCGA: ENSG00000172927
COSMIC: MYEOV

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000172927ENST00000308946Q96EZ4
ENSG00000172927ENST00000308946A0A024R5F1
ENSG00000172927ENST00000441339Q96EZ4
ENSG00000172927ENST00000441339A0A024R5F1
ENSG00000172927ENST00000535407F5H0B3

Expression (GTEx)

0
5
10
15
20
Adipose - Subcutaneous
Adipose - Visceral
Adrenal Gland
Artery - Aorta
Artery - Tibial
Bladder
Brain - Amygdala
Brain - Anterior cingulate cortex
Brain - Caudate
Brain - Cerebellar Hemisphere
Brain - Cerebellum
Brain - Cortex
Brain - Frontal Cortex
Brain - Hippocampus
Brain - Hypothalamus
Brain - Nucleus accumbens
Brain - Putamen
Brain - Spinal cord
Brain - Substantia nigra
Breast - Mammary Tissue
Cells - Cultured fibroblasts
Cells - EBV - transformed lymphocytes
Cervix - Ectocervix
Cervix - Endocervix
Colon - Sigmoid
Colon - Transverse
Esophagus - Gastroesophageal Junction
Esophagus - Mucosa
Esophagus - Muscularis
Fallopian Tube
Heart - Atrial Appendage
Heart - Left Ventricle
Kidney - Cortex
Kidney - Medulla
Liver
Lung
Minor Salivary Gland
Muscle - Skeletal
Nerve - Tibial
Ovary
Pancreas
Pituitary
Prostate
Skin - Not Sun Exposed
Skin - Sun Exposed
Small Intestine - Terminal Ileum
Spleen
Stomach
Testis
Thyroid
Uterus
Vagina
Whole Blood

Protein levels (Protein atlas)

Not detected
Low
Medium
High
N/A

References

Pubmed IDYearTitleCitations
376670962024MYEOV with High Frequencies of Mutations in Head and Neck Cancers Facilitates Cancer Cell Malignant Behaviors.0
384903282024Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.0
376670962024MYEOV with High Frequencies of Mutations in Head and Neck Cancers Facilitates Cancer Cell Malignant Behaviors.0
384903282024Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.0
366981092023MYEOV overexpression induced by demethylation of its promoter contributes to pancreatic cancer progression via activation of the folate cycle/c-Myc/mTORC1 pathway.1
366981092023MYEOV overexpression induced by demethylation of its promoter contributes to pancreatic cancer progression via activation of the folate cycle/c-Myc/mTORC1 pathway.1
332785512021High expression of MYEOV reflects poor prognosis in non-small cell lung cancer.6
349308942021The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma.4
332785512021High expression of MYEOV reflects poor prognosis in non-small cell lung cancer.6
349308942021The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma.4
324208132020Overexpression of MYEOV predicting poor prognosis in patients with pancreatic ductal adenocarcinoma.9
328794442020MYEOV increases HES1 expression and promotes pancreatic cancer progression by enhancing SOX9 transactivity.15
324208132020Overexpression of MYEOV predicting poor prognosis in patients with pancreatic ductal adenocarcinoma.9
328794442020MYEOV increases HES1 expression and promotes pancreatic cancer progression by enhancing SOX9 transactivity.15
301815492019MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-β pathway in NSCLC.25

Citation

Jérôme Moreaux

MYEOV (myeloma overexpressed (in a subset of t (11;14) positive multiple myelomas))

Atlas Genet Cytogenet Oncol Haematol. 2011-10-01

Online version: http://atlasgeneticsoncology.org/gene/395

Historical Card

2002-12-01 MYEOV (myeloma overexpressed (in a subset of t (11;14) positive multiple myelomas)) by  Johannes WG Janssen 

Janssen Institut fur Humangenetik Universitatsklinikum Heidelberg Im Neuenheimer Feld 328 D-69120 Heidelberg, Germany